Skip to main content

Advertisement

SpringerLink
Log in

Cellular and Molecular Biology

Can TILs supplement the TNM staging system (as TNM-Immune)?

  • Correspondence
  • Published:
British Journal of Cancer Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Brummel K, Eerkens AL, de Bruyn M, Nijman HW. Tumour-infiltrating lymphocytes: from prognosis to treatment selection. Br J Cancer. 2023;128:451–8.

    Article  CAS  PubMed  Google Scholar 

  2. Taube JM. Emerging immunologic biomarkers: setting the (TNM-immune) stage. Clin Cancer Res. 2014;20:2023–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Galon J, Bruni D. Tumor immunology and tumor evolution: intertwined histories. Immunity. 2020;52:55–81.

    Article  CAS  PubMed  Google Scholar 

  4. Donnem T, Hald SM, Paulsen EE, Richardsen E, Al-Saad S, Kilvaer TK, et al. Stromal CD8+ T-cell density – a promising supplement to TNM staging in non-small cell lung cancer. Clin Cancer Res. 2015;21:2635–43.

    Article  PubMed  Google Scholar 

  5. Almangush A, Bello IO, Heikkinen I, Hagstrom J, Haglund C, Kowalski LP, et al. Improving risk stratification of early oral tongue cancer with TNM-immune (TNM-I) staging system. Cancers (Basel). 2021;13:3235.

    Article  PubMed  Google Scholar 

  6. Almangush A, Jouhi L, Atula T, Haglund C, Makitie AA, Hagstrom J, et al. Tumour-infiltrating lymphocytes in oropharyngeal cancer: a validation study according to the criteria of the International Immuno-Oncology Biomarker Working Group. Br J Cancer. 2022;126:1589–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. de Jong VMT, Wang Y, Ter Hoeve ND, Opdam M, Stathonikos N, Jozwiak K, et al. Prognostic value of stromal tumor-infiltrating lymphocytes in young, node-negative, triple-negative breast cancer patients who did not receive (neo)adjuvant systemic therapy. J Clin Oncol. 2022;40:2361–74.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391:2128–39.

    Article  PubMed  Google Scholar 

  9. Kilvaer TK, Paulsen EE, Andersen S, Rakaee M, Bremnes RM, Busund LR, et al. Digitally quantified CD8 + cells: the best candidate marker for an immune cell score in non-small cell lung cancer? Carcinogenesis. 2020;41:1671–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, et al. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Helsinki, P.O. Box 21, FI-00014, Helsinki, Finland

    Alhadi Almangush

  2. Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland

    Alhadi Almangush & Antti A. Mäkitie

  3. Institute of Biomedicine, Pathology, University of Turku, Kiinamyllynkatu 10 D 5035, 20520, Turku, Finland

    Alhadi Almangush & Ilmo Leivo

  4. Faculty of Dentistry, Misurata University, Misurata, Libya

    Alhadi Almangush

  5. Department of Otorhinolaryngology – Head and Neck Surgery, University of Helsinki and Helsinki University Hospital, P.O. Box 263, FI-00029 HUS, Helsinki, Finland

    Antti A. Mäkitie

  6. Division of Ear, Nose and Throat Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

    Antti A. Mäkitie

  7. Turku University Central Hospital, 20521, Turku, Finland

    Ilmo Leivo

Authors
  1. Alhadi Almangush
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antti A. Mäkitie
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ilmo Leivo
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The three authors wrote, revised, and approved the final version of the manuscript.

Corresponding author

Correspondence to Alhadi Almangush.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Almangush, A., Mäkitie, A.A. & Leivo, I. Can TILs supplement the TNM staging system (as TNM-Immune)?. Br J Cancer 129, 739–740 (2023). https://doi.org/10.1038/s41416-023-02368-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41416-023-02368-x

  • Springer Nature Limited

Search

Navigation